09:03 AM EDT, 03/18/2025 (MT Newswires) -- Dogwood Therapeutics ( DWTX ) said Tuesday it has begun dosing patients in a phase 2b trial testing Halneuron for chemotherapy-induced neuropathic pain.
The company said it plans to enroll 100 patients by Q4 when it expects to conduct an interim analysis to assess trial progress and make any necessary adjustments.
Shares of the company were up more than 5% in recent Tuesday premarket activity.